Last reviewed · How we verify
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) (tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1)
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) (generic name: tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1) is a vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of COVID-19 in individuals 5 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age, Prevention of COVID-19 in individuals 12 years of age and older.
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) is a COVID-19 vaccine developed by Pfizer Inc. It works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus. The vaccine is administered in two doses, with a booster dose recommended for individuals 5 years of age and older. It is approved for use in individuals 5 years of age and older, as well as in individuals 6 months through 4 years of age. The vaccine has been shown to be effective in preventing severe illness and hospitalization due to COVID-19. It has generated significant revenue for Pfizer Inc., with sales exceeding $62.6 billion. The vaccine's mechanism of action and clinical differentiation set it apart from other COVID-19 vaccines.
At a glance
| Generic name | tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of COVID-19 in individuals 5 years of age and older
- Prevention of COVID-19 in individuals 6 months through 4 years of age
- Prevention of COVID-19 in individuals 12 years of age and older
- Prevention of COVID-19 in individuals 12 years of age and older as a booster dose
- Prevention of COVID-19 in individuals 5 years of age and older as a booster dose
- Prevention of COVID-19 in individuals 6 months through 4 years of age as a booster dose
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pain medications
- Anticoagulants
- Antiplatelets
- Heparin
- Thrombolytics
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants
- Monoamine oxidase inhibitors (MAOIs)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) CI brief — competitive landscape report
- Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
What is Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)?
What is Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) used for?
Who makes Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)?
What is the generic name of Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)?
What drug class is Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) in?
What development phase is Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) in?
What does Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) target?
Related
- Drug class: All vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of COVID-19 in individuals 5 years of age and older
- Indication: Drugs for Prevention of COVID-19 in individuals 6 months through 4 years of age
- Indication: Drugs for Prevention of COVID-19 in individuals 12 years of age and older
- Compare: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) vs similar drugs
- Pricing: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) cost, discount & access